Navigation Links
BioMarin to Host Third Quarter 2010 Financial Results Conference Call and Webcast on Thursday, October 28 at 5:00 p.m. ET
Date:10/7/2010

NOVATO, Calif., Oct. 7 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 28, at 5:00 p.m. ET to discuss third quarter 2010 financial results.U.S. / Canada Dial-in Number:  866.202.3048International Dial-in Number:  617.213.8843Participant Code: 60493555Replay Dial-in Number: 888.286.8010Replay International Dial-in Number: 617.801.6888Replay Code: 45911037Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

Contacts:InvestorsEugenia Shen BioMarin Pharmaceutical Inc. (415) 506-6570
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin to Present at the Barclays Capital Global Healthcare Conference
2. BioMarins Chief Executive Jean-Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times
3. BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
4. BioMarin to Present at the Morgan Stanley Healthcare Conference
5. BioMarin to Present at the Baird Healthcare Conference
6. BioMarin to Present at the Jefferies Healthcare Conference
7. BioMarin to Present at the Goldman Sachs Healthcare Conference
8. BioMarin to Present at the Deutsche Bank Health Care Conference
9. BioMarin to Present at the Baird Growth Stock Conference
10. BioMarin Announces First Quarter 2009 Financial Results
11. BioMarin to Host First Quarter 2009 Financial Results Conference Call and Webcast on Thursday, April 30 at 5:00 p.m. ET (23:00 CET)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Jan. 17, 2017  Northwell Health today announced ... of precision cancer research. As ... health care provider, Northwell Health diagnoses and treats ... is a Germany -based oncology ... Together they will greatly expand cancer biobanking activities ...
(Date:1/17/2017)... Hong Kong (PRWEB) , ... January 17, 2017 ... ... management software, and NetDimensions, a global provider of learning and performance management systems ... for the mainland China market. , “In the life sciences industry, organizations must ...
(Date:1/16/2017)... NY (PRWEB) , ... January 16, 2017 , ... ... New Jersey laws precedential publication its decision on the appeal filed by India-based ... lawsuit of breach of contract against DPCL and one of its Dishman Group’s ...
(Date:1/14/2017)... ... January 14, 2017 , ... Seattle-based ... complete end-to-end genome assemblies to researchers around the globe. Long considered a ... in answering a wide range of scientific questions. The announcement was made ...
Breaking Biology Technology:
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
(Date:12/8/2016)... PUNE, India , Dec. 8, 2016 Market Research ... and Service Market. The global Mobile Biometric Security and Service Market ... period 2016 to 2022. Market Highlights: ... , , ... fast pace due to the increasing need of authentication and security ...
(Date:12/7/2016)... , December 7, 2016 BioCatch , ... expansion of its patent portfolio, which grew to over 40 granted and ... , , ... recently filed patent entitled " System, Device, and Method Estimating ... that enables device makers to forego costly hardware components needed to estimate ...
Breaking Biology News(10 mins):